Request Demo

Last update 12 Sep 2025

Lecanemab

Last update 12 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-amyloid beta protofibril antibody, Immunoglobulin G1, anti-(human beta-amyloid protofibril) (human-mus musculus monoclonal BAN2401 heavy chain), disulfide with human-mus musculus monoclonal BAN2401 light chain, dimer, lecanemab-irmb

+ [8]

Target

APP

Action

inhibitors

Mechanism

APP inhibitors(Beta amyloid A4 protein inhibitors)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersOther Diseases

Active Indication

Dementia due to Alzheimer's disease (disorder)Mild cognitive disorderAlzheimer Disease+ [2]

Inactive Indication-

Originator Organization

Active Organization

+ [4]

Inactive Organization-

License Organization

BioArctic AB

Biogen, Inc.

Shanghai Pharmaceuticals Holding Co., Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (06 Jan 2023),

Alzheimer Disease

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Priority Review (China), Innovative Licensing and Access Pathway (United Kingdom), Priority Review (Japan)

Structure/Sequence

Sequence Code 315606586L

Source: *****

Sequence Code 315606587H

Source: *****

Clinical Trials associated with Lecanemab

NCT07152418

/ Not yet recruitingNot ApplicableIIT

A Study on the Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively. However, some patients still progress slowly to the moderate stage during treatment despite maintaining low Aβ/tau pathological protein loads. For such cases, patients and their families are fully informed about the potential lack of efficacy with continued treatment, and the decision is left to their discretion. Information regarding whether treatment is continued is documented and followed up to determine whether sustained benefits can be achieved. Previous further studies on lecanemab suggest that patients with low or absent tau pathology derive more significant clinical benefits, though large-sample validation remains lacking. This project will therefore enroll patients at clinical stages 3-4 (0.5 ≤ CDR ≤ 1) and monitor those progressing to moderate AD (CDR = 2) during monoclonal antibody therapy. Using tau pathology stratification, the study aims to identify which AD patients are most suitable for monoclonal antibody treatment and evaluate whether therapy continuation yields sustained benefits in patients progressing to moderate dementia, as well as whether patient selection should integrate both pathological (a-c stage) and clinical diagnoses.

Start Date01 Sep 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06992804

/ RecruitingEarly Phase 1IIT

The Efficacy and Safety of Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease

The goal of this study is to explore the efficacy and safety of near-infrared light combined with lecanemab in patients with mild Alzheimer's disease (AD).
This study will employ a randomized, double-blind, sham-controlled method with an open-label extension phase. This trial contains the core phase and an extension phase. During the core phase, eligible subjects were selected and randomized (experimental group: control group = 1:1). The subjects who entered the experimental group received treatment with a near-infrared light therapy device combined with lecanemab for 16 weeks. The subjects who entered the control group received treatment with a near-infrared light therapy device simulator (sham stimulation) combined with lecanemab for 16 weeks. After completing the core phase, patients from both groups of the core phase are eligible to enter the extension phase. In the extension phase, all the participants were treated with a near-infrared light therapy device combined with lecanemab up to week 48.

Start Date28 May 2025

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

ChiCTR2500102030

Phase 4IIT

Study on the Efficacy and Safety of Luncaner in the Treatment of Moderate to Severe Alzheimer's Disease

Start Date01 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lecanemab

100 Translational Medicine associated with Lecanemab

100 Patents (Medical) associated with Lecanemab

502

Literatures (Medical) associated with Lecanemab

01 Feb 2026·Neural Regeneration Research

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Article

Author: Guo, Wanshu ; Sha, Sha ; Ren, Lina ; Qu, Le ; Li, Ying ; Cao, Yunpeng ; Xing, Xiaona ; Wang, Yan

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.

01 Feb 2026·Neural Regeneration Research

Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer’s disease

Article

Author: Hoi, Maggie Pui Man ; Lei, Chon Lok ; Yue, Qian ; Wan, Huaibin ; Zhang, Zaijun ; Li, Shang

Drug development for Alzheimer’s disease is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis. More recently, advances in the development of Lecanemab, an anti-amyloid-β monoclonal antibody, have shown positive results in reducing brain A burden and slowing cognitive decline in patients with early-stage Alzheimer’s disease in the Phase III clinical trial (Clarity Alzheimer’s disease). Despite these promising results, side effects such as amyloid-related imaging abnormalities (ARIA) may limit its usage. ARIA can manifest as ARIA-E (cerebral edema or effusions) and ARIA-H (microhemorrhages or superficial siderosis) and is thought to be caused by increased vascular permeability due to inflammatory responses, leading to leakages of blood products and protein-rich fluid into brain parenchyma. Endothelial dysfunction is an early pathological feature of Alzheimer’s disease, and the blood–brain barrier becomes increasingly leaky as the disease progresses. In addition, APOE4, the strongest genetic risk factor for Alzheimer’s disease, is associated with higher vascular amyloid burden, increased ARIA incidence, and accelerated blood–brain barrier disruptions. These interconnected vascular abnormalities highlight the importance of vascular contributions to the pathophysiology of Alzheimer’s disease. Here, we will closely examine recent research evaluating the heterogeneity of brain endothelial cells in the microvasculature of different brain regions and their relationships with Alzheimer’s disease progression.

01 Sep 2025·CURRENT PROTEIN & PEPTIDE SCIENCE

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment

Article

Author: Khan, Yumna ; Fatima, Rabab ; Ramalingam, Prasanna Srinivasan ; Maqbool, Mudasir ; Bisht, Ajay Singh ; Khan, Mohammad Gayoor ; Hussain, Md Sadique

Alzheimer's disease (AD) is a progressive condition that causes the degeneration of nerve cells, leading to a decline in cognitive abilities and memory impairment, significantly affecting millions around the globe. The primary pathological feature of AD is the buildup of amyloid-β (Aβ) plaques in the brain, which has become a major target for therapeutic strategies. This thorough review examines the progress made in next-generation therapies that concentrate on monoclonal antibodies (mAbs) aimed at Aβ. We explore how these antibodies function, their effectiveness in clinical settings, and their safety profiles, specifically discussing notable mAbs, such as aducanumab, donanemab, lecanemab, etc. This review also addresses the difficulties related to Aβ- targeted treatments. Furthermore, it examines the advancing field of biomarker development and tailored medicine strategies designed to improve the accuracy of AD treatment. By integrating the latest findings from clinical trials and new research, this review offers an in-depth evaluation of the possibilities and challenges associated with mAbs in modifying the progression of AD. Future considerations regarding combination therapies and novel drug delivery methods are also examined, emphasizing the necessity for ongoing research to achieve significant advancements in managing AD. Through this review, we seek to provide clinicians, researchers, and policymakers with insights into the current landscape and future directions of Aβ-targeted therapies, promoting a deeper understanding of their role in addressing AD.

1,257

News (Medical) associated with Lecanemab

05 Sep 2025

·www.fiercepharma.com

Fierce Pharma Asia—Novartis' $5B Argo deal; Eisai's subcutaneous Leqembi nod; HKEX chastises Henlius

Novartis' siRNA deal with Argo Biopharmaceutical, the FDA's approval for Leqembi Iqlik and the Hong Kong Stock Exchange's sanctions against Shanghai Henlius Biotech and its former CEO made our news this week. Novartis is tapping into Argo Biopharmaceutical's siRNA capabilities again in a deal worth up to $5.2 billion. The FDA approved a subcutaneous version of Eisai and Biogen's Leqembi. The Hong Kong Stock Exchange issued sanctions against Shanghai Henlius Biotech and its former CEO over a questionable reallocation of IPO proceeds. And more.1. Novartis returns to Argo for multifaceted $5B cardiovascular collabNovartis has returned to China siRNA biotech Argo Biopharmaceutical for more cardiovascular assets. In a deal potentially worth $5.2 billion, Novartis gained options to two discovery-stage molecules for severe hypertriglyceridemia and mixed dyslipidemia, plus a right of first negotiation to ANGPTL3—an RNAi therapeutic—following a combination trial in dyslipidemia. Argo gets $160 million upfront in the deal.2. Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosingThe FDA has approved a subcutaneous version of Eisai and Biogen’s Leqembi as maintenance treatment for Alzheimer’s disease. The drug, called Leqembi Iqlik, is given once a week via an autoinjector. Eisai hopes the more convenient formulation could save healthcare resources and increase uptake of the medicine. The company also initiated an FDA rolling submission for Leqembi Iqlik as a starting dose.3. Hong Kong exchange disciplines Henlius over $117M asset management lapse (PDF)The Hong Kong Stock Exchange is censuring Shanghai Henlius Biotech and sending its former CEO Scott Shi-Kau Liu to 26 hours of training on regulations and listing compliance rules. The issue dates back to the biotech’s IPO in 2019. The exchange found that Henlius and Liu breached its rules by redirecting $117 million, or 29% of the biotech’s IPO proceeds, to a questionable investment vehicle even though such use was not listed in Henlius’ prospectus. Liu greenlighted the deal, signed on the day of the IPO by Henlius’ then-Chief Financial Officer Zidong Zhang, Ph.D., without examining the agreement document or bringing the matter to the board for consideration. Henlius and Liu did not contest their respective breaches and agreed to their sanctions, according to the exchange.4. Amgen-Zai stomach cancer candidate takes a turn with 'attenuated' OS benefits at final phase 3 analysisThe overall survival benefit observed for Amgen and Zai Lab’s anti-FGFR2b drug bemarituzumab in a phase 3 stomach cancer trial has “attenuated,” Zai said. The study, coded Fortitude-101, tested adding the drug to chemotherapy in first-line, HER2-negative gastric or gastroesophageal junction cancer with FGFR2b overexpression. Back in June, the pair said the study met its primary endpoint of overall survival at an interim analysis.5. AstraZeneca, exiting production digs in India, surrenders local manufacturing licenseAstraZeneca has handed in its manufacturing license in India as the British pharma plans to exit from its lone production facility in the country. In 2023, the company disclosed its intent to shutter its Bengaluru plant “in due course.” After failing to find a suitable contract manufacturer to take over the place, the company is still aiming to sell the facility. 6. India’s drug regulator eyes lighter oversight, more AI to boost efficiency (Reuters)To increase efficiency, India’s drug regulator is working to reduce certain requirements and processing time. “We’re trying to increase our efficiency, cutting down on regulations so that we create more and more resources within our system,” the Central Drugs Standard Control Organisation's Rajeev Raghuvanshi told Reuters on the sidelines of an industry event.Other News of Note: 7. Lilly links up with JD Health for DTC obesity, diabetes drug sales in China8. Korean ADC developers debate strategies to counter China’s rapid rise (Korea Biomedical Review)9. Roche’s Chugai adds new safety measure for Sarepta’s Elevidys in Japan (Regulatory tracker)10. Fosun rises again, inking 3rd inflammatory disease deal in 3 weeks11. Henlius, Organon win FDA nods for biosimilars to Amgen’s Prolia, Xgeva (Release)

Phase 3License out/inDrug ApprovalIPOClinical Result

04 Sep 2025

·www.globenewswire.com

Algernon Pharmaceuticals Announces Name Change to Algernon Health

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is changing its name to Algernon Health. The planned name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease (AD) diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared, optimized brain-specific Positron Emission Tomography (PET) scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared to standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid, and private insurance in the U.S. Amyloid plaques are aggregates of mis-folded proteins that form in the spaces between nerve cells and are known to play a central role in AD and are associated with neural degeneration. The amyloid plaques typically first develop in the areas of the brain concerned with memory and other cognitive functions. A positive amyloid confirmation through a PET scan or a spinal tap must be first established before a patient can be treated with either Kisunla or Leqembi, the two U.S. FDA-approved, AD monoclonal antibody treatment therapies that remove amyloid plaque from the brain. These new treatments were developed by Eli Lilly, and Eisai and Biogen, respectively, and are also covered by U.S. Medicare, Medicaid, and private insurance providers. After the first AD drug treatment was approved, in a post-earnings call, GE HealthCare CEO Peter Arduini called it a “profound growth opportunity” for all providers offering PET scans and molecular imaging. The introduction of dedicated neuroimaging clinics provides the Company with a clear pathway to revenue utilizing a technology already U.S. FDA-cleared and covered by U.S. Medicare and Medicaid and private insurance. The Algernon clinics will also offer additional brain PET scans for other forms of dementia, epilepsy, neuro-oncology, and movement disorders, to further expand the provision of healthcare to patients in need and expand clinic revenues. This strategic entry by Algernon into dedicated neuroimaging clinics is significantly based on the fact that the vast majority of PET/CT scanners in the U.S. are prioritized as cancer diagnostic and theranostic tools, and are also dedicated to cardiac imaging. Consequently, there is an insufficient supply of scanners to serve the rapidly expanding AD diagnostics market. The shortage of PET scanners for brain specific scanning also has an impact beyond immediate patient care. With 162 AD drugs under development, there is also a significant opportunity to provide brain specific PET scan imaging services to drug development companies and contract research organizations engaged in clinical trials, as another source of revenue for Algernon. Algernon will update the market shortly on its upcoming expansion and growth plans including the location of it first U.S. flagship neuroimaging clinic. Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil. Algernon is currently reviewing its repurposed chronic kidney disease drug program which features the drug repirinast as its lead molecule. Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com About Algernon Health Algernon Health is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Radiation Therapy

03 Sep 2025

·www.prnewswire.com

BioArctic's founders intend to divest minor part of their shareholding

STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on September 3, 2025, at 5:35 p.m. CET. For further information, please contact: Oskar Bosson, Vice President Communications and Investor Relations E-mail : [email protected] Telephone: +46 70 410 71 80 About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit . This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

100 Deals associated with Lecanemab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lecanemab	-	DB14580

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eisai Europe Ltd.	22 Aug 2024
Mild cognitive disorder	United Kingdom	Eisai Co., Ltd.	22 Aug 2024
Alzheimer Disease	United States	Eisai, Inc.	06 Jan 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 1	Japan	Eisai Co., Ltd.	01 Sep 2013
Brain Injuries, Traumatic	Preclinical	United States	BioArctic AB	15 Nov 2023
Down Syndrome	Preclinical	United States	BioArctic AB	15 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01767311 (FDA_CDER) Manual	Phase 2	Alzheimer Disease	856	LEQEMBI 10 mg/kg Every Two Weeks	mmqlhtsaoj(dhkrljrgsd) = LEQEMBI had a 64% likelihood of 25% or greater slowing of progression on the primary endpoint relative to placebo at Week 53, which did not meet the prespecified success criterion of 80%. ijhdfxelna (qvolhalolh )	-	29 Aug 2025
				Placebo
NCT03887455 (Clarity AD, NEWS) Manual	Phase 3	Alzheimer Disease	-	Leqembi	biiohdvtqc(tzftsitmvc) = ayeokddelr qipioisizy (ikdxybekah )	Positive	12 Aug 2025
				placebo	biiohdvtqc(tzftsitmvc) = mcfumibbvv qipioisizy (ikdxybekah )
NCT03887455 (Clarity AD OLE, Company_Website) Manual	Not Applicable	Alzheimer Disease Maintenance	-	lecanemab-irmb SC	tdotkfvsyv(scrracmrku) = Data supports that transitioning to a weekly 360 mg SC AI dose of lecanemab after 18 months of initiation dose (10 mg/kg IV biweekly) maintains clinical and biomarker benefits comparable to continued biweekly IV dosing. Clinical and biomarker responses at 48 months with monthly IV maintenance dosing are similar to the responses with ongoing biweekly dosing whether patients are amyloid positive (>30 CL) or negative (<30 CL) at 18 months. Data shows the 500 mg SC AI has equivalent exposure as the initial treatment regimen of 10 mg/kg IV biweekly up to 18 months for amyloid removal, efficacy, and ARIA-E. zxgokhkpbd (ofcrvjwjqj ) View more	Positive	30 Jul 2025
				lecanemab IV
Company_Website Manual	Not Applicable	Alzheimer Disease	178	Lecanemab	fquiwiyoix(svjjbjgrud) = 83.6% of patients either remained at the same clinical stage or improved from mild dementia to MCI (stable: 76.9%, improvement: 6.7%) mvvxmlxdmy (dkuydvksgt ) View more	Positive	30 Jul 2025
P12-3.019 (AAN2025)	Not Applicable	-	-	Lecanemab	xuodvlgotv(grkebionic) = jzydedtxfs ognkgzglrx (fsdqdfgere, 91.1)	-	07 Apr 2025
NCT03887455 (Clarity AD, PRNewswire) Manual	Phase 3	Alzheimer Disease	1,795	lecanemab	dkcvhtzjbo(ncjmyoaogw) = ectwqtsrjc gknnoxxshl (hsqmdqogap ) View more	Positive	30 Jul 2024
				Placebo	dkcvhtzjbo(ncjmyoaogw) = xljtdedaos gknnoxxshl (hsqmdqogap ) View more
NCT03887455 (Clarity AD, Pubmed \| Alzheimers Res Ther) Manual	Phase 3	Alzheimer Disease ApoE e4 carriers \| ApoE ε4 homozygous participants	3,407	Lecanemab 10 mg/kg biweekly	xlpijkioth(hpikfvfrmw) = jprmkylicj zouxfoitdu (vfcwgvkcma ) View more	Positive	10 May 2024
				placebo (Core Study)	qsivehlyct(vuhuokecpa) = muibeeooar jcwnivcrwv (wyybxybumq )
NCT03887455 (Clarity AD, AAN2024)	Phase 3	Alzheimer Disease amyloid PET centiloid levels	-	Lecanemab 10 mg/kg biweekly	ptldhjcajm(zggvqpvexg) = cpdzwhzizp hinoerrklm (uwfusowzwj )	Positive	09 Apr 2024
				Placebo	ptldhjcajm(zggvqpvexg) = xjmnkpieuw hinoerrklm (uwfusowzwj )
NCT03887455 (Clarity AD, PRNewswire \| NEWS \| Corporate Publications) Manual	Phase 3	Alzheimer Disease	898	LEQEMBI (SC)	pcwbrblnmr(skfbmqhtoc) = rcmudqtaka xvnydktmnb (wpjtkiywwe, 2.27) View more	Positive	25 Oct 2023
				LEQEMBI (IV)	pcwbrblnmr(skfbmqhtoc) = ocugzdoeso xvnydktmnb (wpjtkiywwe, 1.14) View more
NCT03887455 (Clarity AD, FDA) Manual	Phase 3	Alzheimer Disease ApoE ε4	1,464	LEQEMBI 10 mg/kg	sivrexwqqo(ufzzwsqjsi) = epozjckorc pylrmktigd (rpbaiwcdcr ) Met View more	Positive	06 Jan 2023
				Placebo	sivrexwqqo(ufzzwsqjsi) = pgsedqmicw pylrmktigd (rpbaiwcdcr ) Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis